Insider Selling: Cellebrite DI (NASDAQ:CLBT) CFO Sells $683,602.92 in Stock

Cellebrite DI Ltd. (NASDAQ:CLBT) CFO David Barter sold 41,734 shares of Cellebrite DI stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the transaction, the chief financial officer directly owned 334,219 shares in the company, valued at approximately $5,474,507.22. The trade was a 11.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Cellebrite DI Stock Down 1.2%

Cellebrite DI stock traded down $0.19 during midday trading on Friday, hitting $15.94. The company’s stock had a trading volume of 1,368,357 shares, compared to its average volume of 1,968,646. Cellebrite DI Ltd. has a 12 month low of $11.02 and a 12 month high of $19.98. The company has a market capitalization of $3.98 billion, a PE ratio of 56.93, a price-to-earnings-growth ratio of 1.97 and a beta of 1.17. The stock’s 50-day moving average price is $13.77 and its 200-day moving average price is $14.53.

Hedge Funds Weigh In On Cellebrite DI

Institutional investors have recently bought and sold shares of the stock. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its position in Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares in the last quarter. CWM LLC grew its holdings in shares of Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after acquiring an additional 889 shares in the last quarter. SkyView Investment Advisors LLC grew its holdings in shares of Cellebrite DI by 2.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after acquiring an additional 970 shares in the last quarter. Alamea Verwaltungs GmbH increased its stake in shares of Cellebrite DI by 4.3% in the fourth quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock worth $444,000 after acquiring an additional 1,018 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its position in Cellebrite DI by 45.1% during the fourth quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock valued at $72,000 after purchasing an additional 1,238 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on CLBT. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. DA Davidson began coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Needham & Company LLC dropped their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cellebrite DI presently has an average rating of “Moderate Buy” and an average target price of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.